<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Effect of antihypertensive treatment on kidney function in primary (essential) hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Effect of antihypertensive treatment on kidney function in primary (essential) hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Effect of antihypertensive treatment on kidney function in primary (essential) hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johannes FE Mann, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karl F Hilgers, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney function may deteriorate because of uncontrolled hypertension. Even minimal elevations in blood pressure (BP) are associated with increased renal arteriosclerosis in autopsies [<a href="#rid1">1</a>]. Since adequate control of hypertension may slow the rate of kidney dysfunction [<a href="#rid2">2</a>], the effects of antihypertensive therapy on kidney function need to be carefully considered.</p><p>Antihypertensive therapy has both acute and chronic effects on kidney function in patients with primary hypertension (formerly called "essential" hypertension). In early disease, for example, kidney function is usually normal; in this setting, lowering the BP induces little change in glomerular filtration rate (GFR) [<a href="#rid3">3</a>] (see  <a class="medical medical_review" href="/d/html/3873.html" rel="external">"Renal effects of ACE inhibitors in hypertension"</a>). Black patients may have an initial decrease in GFR compared with an increase in White patients [<a href="#rid4">4</a>].</p><p>This topic reviews the chronic and acute effects of antihypertensive therapy on kidney function in patients with primary hypertension. Goal BP and the choice of antihypertensive agent are discussed in separate topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CHRONIC EFFECTS</span><span class="headingEndMark"> — </span>Patients with prolonged uncontrolled hypertension are at increased risk of developing chronic kidney disease [<a href="#rid5">5</a>]. The risk of this complication is much greater in Black patients and in patients with more severe hypertension  (<a class="graphic graphic_figure graphicRef62524" href="/d/graphic/62524.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/3855.html" rel="external">"Burden of hypertension in Black individuals"</a>.)</p><p>It must be emphasized, however, that the percentage of patients with mild hypertension who develop end-stage kidney disease (ESKD) is relatively small, being less than 1 percent after 16 years in the Multiple Risk Factor Intervention Trial (MRFIT) trial [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/3824.html" rel="external">"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis", section on 'Incidence of kidney failure'</a>.)</p><p>Prolonged blood pressure (BP) control will usually minimize the degree of renal damage, leading to a stable plasma creatinine concentration [<a href="#rid2">2</a>]. There are, however, patients in whom proteinuria develops or the plasma creatinine concentration continues to rise slowly over a period of years despite seemingly adequate antihypertensive therapy. This is most likely to occur in Black patients, in patients who have underlying chronic kidney disease (CKD) or a family history of ESKD, and in patients with vascular disease, which is suggested by the presence of older age, higher baseline BP, or hyperuricemia.</p><p>Hyperuricemia (independent of diuretic therapy) has been attributed to a reduction in renal blood flow induced by the arterial and arteriolar disease [<a href="#rid6">6</a>]. However, some have proposed that it may have a key causal role in the onset of primary hypertension, with increased uric acid levels resulting in endothelial dysfunction, vasculopathy, and elevated BP [<a href="#rid7">7</a>]. Nevertheless, there is so far little evidence that treatment of hyperuricemia has a role in the treatment of hypertension.</p><p>Why renal damage may progress despite seemingly adequate control of the hypertension is uncertain. It is possible that some of these patients have a different kidney disease that is worsened by hypertension (see  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>). Among Black patients, the increased risk for progression of kidney disease is likely related to a genetic defect with less contribution from hypertension. (See  <a class="medical medical_review" href="/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes", section on 'FSGS in Black patients'</a>.)</p><p>Alternatively, aiming for a BP of 140/85 to 90 mmHg may be inadequate to prevent renal damage in some patients. It is possible that maintaining a lower BP would be more beneficial in this setting [<a href="#rid8">8</a>] (see  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>). The observation from a large epidemiologic study that higher BP <strong>within the normal range</strong> may be associated with kidney injury over a period of many years is compatible with the hypothesis that more intensive BP control may be beneficial in some patients [<a href="#rid9">9</a>]. That hypothesis, however, was not supported by the kidney outcomes of the Systolic Blood Pressure Intervention Trial (SPRINT), nor was it supported by outcomes in the Secondary Prevention of Small Subcortical Strokes (SPS3) study (see  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>). Moreover, based upon the findings of the Third National Health and Nutrition Examination Survey of a representative sample of the United States population, an estimated 5.6 million people have an elevated serum creatinine that is strongly related to inadequate treatment of hypertension [<a href="#rid10">10</a>].</p><p>The potential superiority of angiotensin-converting enzyme (ACE) inhibitors may be due to the fact that, at least in animal models, these drugs lower the intraglomerular pressure by preferentially decreasing the resistance at the efferent (postcapillary) glomerular arteriole [<a href="#rid11">11</a>]. In human studies, ACE inhibitors or angiotensin receptor blockers (ARBs) slow the progression of diabetic and nondiabetic nephropathy, particularly in the presence of proteinuria [<a href="#rid12">12</a>].</p><p>In some studies, other drugs that presumably lack this preferential effect on efferent arteriolar resistance have also been found to slow the rate of renal damage, similar to ACE inhibitors [<a href="#rid13">13</a>]. However, most studies support the notion that ACE inhibitors are more effective in this regard in many forms of proteinuric kidney disease [<a href="#rid2">2</a>]. It is difficult to assess the relative importance of the specific type of drug versus the effective reduction of BP or the relief of other major risk factors [<a href="#rid2">2,14</a>]. However, these considerations are based upon studies performed in patients with known kidney disease, and their importance for patients with primary hypertension is unknown. (See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ACUTE EFFECTS</span><span class="headingEndMark"> — </span>Despite the long-term renal benefit of antihypertensive therapy in most patients, the initial reduction in blood pressure (BP) may be associated with a transient elevation in the plasma creatinine concentration, which reflects a fall in the glomerular filtration rate (GFR). This effect is most likely to occur with moderate to severe hypertension. An increase in serum creatinine with initial antihypertensive treatment is usually associated with one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A relatively marked and rapid reduction in BP, often exceeding 25 mmHg [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), or direct renin inhibitor, particularly in those with atherosclerotic vascular disease or an acute lowering of blood pressure. In the presence of a drug-induced fall in renal perfusion pressure, angiotensin II participates in the autoregulatory response that attempts to maintain the GFR; this contribution is blocked by an ACE inhibitor or ARB. The development of acute kidney injury (AKI) is most common in bilateral renal artery stenosis. (See  <a class="medical medical_review" href="/d/html/3873.html" rel="external">"Renal effects of ACE inhibitors in hypertension"</a> and  <a class="medical medical_review" href="/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis", section on 'Medical therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent volume depletion, most often due to diuretic therapy, which makes maintenance of the GFR more angiotensin II dependent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of nonsteroidal antiinflammatory drugs.</p><p></p><p>The impairment in GFR following the institution of antihypertensive therapy is usually moderate and at least partially reversible within several weeks. The proper approach varies with the clinical setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Temporarily discontinuing treatment is indicated in patients who have had an excessive reduction in BP. In this setting, therapy can usually be safely restarted at a lower dose. Particular caution is needed with ACE inhibitors and ARBs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuing antihypertensive therapy is reasonable as long as the rise in the plasma creatinine concentration is less than 30 percent of the pretreatment level. This is based upon the evidence that persistent BP control will lead to regression of arteriolar hyperplasia, and the plasma creatinine concentration will generally return to or occasionally fall below the pretreatment level over a period of weeks to months. In many studies, ACE inhibitors produced a transient initial rise in serum creatinine but a beneficial effect on kidney function and other outcomes in the long term [<a href="#rid16">16-18</a>].</p><p></p><p class="bulletIndent1">In a population-based cohort study from the United Kingdom, impairment of GFR following institution of renin-angiotensin system blockade was associated with more renal and cardiovascular events in the long term [<a href="#rid19">19</a>]. This observation, however, may represent the underlying risk factors in the population rather than a direct effect of the GFR impairment; by contrast, analyses of randomized trials of renin-angiotensin system inhibitors failed to confirm such an association [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversing volume depletion by discontinuing excessive diuretic therapy may be beneficial when an unacceptable decline in GFR follows the institution of an ACE inhibitor [<a href="#rid21">21</a>]. If this is ineffective or the patient has not been taking a diuretic, then switching to a drug that does not reduce intraglomerular pressure (such as a calcium channel blocker) is indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for unrecognized bilateral renal artery stenosis should be considered, particularly in older patients with extensive atherosclerosis elsewhere, or if kidney function rapidly deteriorates soon after starting a drug that inhibits the renin-angiotensin system. The selection of patients who should be screened for renal artery stenosis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension", section on 'Clinical clues for renovascular hypertension'</a>.)</p><p></p><p class="headingAnchor" id="H1626814648"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H1036798"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Antihypertensive therapy has both acute and chronic effects on kidney function in patients with primary hypertension (formerly called "essential" hypertension). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Goal blood pressure (BP) and the choice of antihypertensive agent are discussed in separate topics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged BP control will usually minimize the degree of renal damage, leading to a stable plasma creatinine concentration. However, proteinuria may develop or the plasma creatinine concentration may continue to slowly rise in some patients. (See <a class="local">'Chronic effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the long-term renal benefit of antihypertensive therapy, the initial reduction in BP may be associated with a transient elevation in the plasma creatinine concentration. The development of acute kidney injury (AKI) is usually associated with a relatively marked reduction in BP; the use of an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), or direct renin inhibitor; concurrent volume depletion; and nonsteroidal antiinflammatory drugs. (See <a class="local">'Acute effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impairment in glomerular filtration rate (GFR) following the institution of antihypertensive therapy is usually reversible. The proper approach to treatment varies with the clinical setting. A mild impairment (a rise in serum creatinine of less than 30 percent of the pretreatment level) does not require altering the antihypertensive therapy in most cases. (See <a class="local">'Acute effects'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ninomiya T, Kubo M, Doi Y, et al. Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama Study. J Am Soc Nephrol 2007; 18:2135.</a></li><li><a class="nounderline abstract_t">Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244.</a></li><li><a class="nounderline abstract_t">Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1997; 29:720.</a></li><li><a class="nounderline abstract_t">Mitchell HC, Smith RD, Cutler RE, et al. Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. Am J Kidney Dis 1997; 29:897.</a></li><li><a class="nounderline abstract_t">Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13.</a></li><li><a class="nounderline abstract_t">Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817.</a></li><li><a class="nounderline abstract_t">Reynolds T. Serum uric acid, the endothelium and hypertension: an association revisited. J Hum Hypertens 2007; 21:591.</a></li><li><a class="nounderline abstract_t">Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29:641.</a></li><li><a class="nounderline abstract_t">Perneger TV, Nieto FJ, Whelton PK, et al. A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study. JAMA 1993; 269:488.</a></li><li><a class="nounderline abstract_t">Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161:1207.</a></li><li><a class="nounderline abstract_t">Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155:1073.</a></li><li><a class="nounderline abstract_t">Mulrow CD, Townsend RR. Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: proteinuria and blood pressure levels? Ann Intern Med 2003; 139:296.</a></li><li><a class="nounderline abstract_t">Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713.</a></li><li><a class="nounderline abstract_t">Lo SH, Mo KL, Wong KS, et al. Aristolochic acid nephropathy complicating a patient with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2004; 19:1913.</a></li><li><a class="nounderline abstract_t">Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007; 18:960.</a></li><li><a class="nounderline abstract_t">Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685.</a></li><li><a class="nounderline abstract_t">Hirsch S, Hirsch J, Bhatt U, Rovin BH. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success. Am J Nephrol 2012; 36:430.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Remuzzi G. Dealing with renin-angiotensin inhibitors, don't mind serum creatinine. Am J Nephrol 2012; 36:427.</a></li><li><a class="nounderline abstract_t">Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 2017; 356:j791.</a></li><li><a class="nounderline abstract_t">Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017; 91:683.</a></li><li><a class="nounderline abstract_t">Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222.</a></li></ol></div><div id="topicVersionRevision">Topic 3822 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582160" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12965979" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9159306" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9186076" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7494564" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blood pressure and end-stage renal disease in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7447188" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Serum uric acid in essential hypertension: an indicator of renal vascular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541384" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Serum uric acid, the endothelium and hypertension: an association revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040451" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419668" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343443" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7748051" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term effects of antihypertensive agents on proteinuria and renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12965986" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: proteinuria and blood pressure levels?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732338" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15199198" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Aristolochic acid nephropathy complicating a patient with focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301190" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724055" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128144" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128084" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dealing with renin-angiotensin inhibitors, don't mind serum creatinine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28279964" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27927602" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893255" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Captopril-induced renal insufficiency and the role of sodium balance.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
